Use: Labeled indications
- ROWASA is indicated for the treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis in adults.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE ROWASA is indicated for the treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis in adults. ROWASA is an aminosalicylate indicated for treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis in adults. (1)
Contraindications
4 CONTRAINDICATIONS ROWASA is contraindicated in patients with known or suspected hypersensitivity to salicylates, aminosalicylates, sulfites or any other component of this medication [see Warnings and Precautions (5.3)]. Known or suspected hypersensitivity to salicylates, aminosalicylates, sulfites or any other of the ingredients in ROWASA. (4, 5.1)
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
2 DOSAGE AND ADMINISTRATION Evaluate renal function before initiating therapy with ROWASA [see Warnings and Precautions (5.1)]. Recommended Dosage The recommended dosage is one rectal instillation (4 grams) once a day, preferably at bedtime, and retained for approximately eight hours for 3 to 6 weeks depending on symptoms and sigmoidoscopic findings.
Administration Instructions
- Shake the bottle to ensure the suspension is homogeneous.
- Remove the protective sheath from the applicator tip.
- Assume the correct body position: o Lie on the left side with the lower leg extended and the upper right leg flexed forward for balance. o Alternatively, sit in the knee to chest position.
- Gently insert the applicator tip in the rectum pointing toward the umbilicus.
- Steadily squeeze the bottle to discharge the medication.
- Remain in the position for at least 30 minutes. Administer at bedtime with the objective of retaining it all night.
- Drink an adequate amount of fluids during treatment [see Warnings and Precautions (5.7)].
- Evaluate renal function prior to initiation of ROWASA and periodically while on therapy. (2, 5.1)
- The recommended dosage is one rectal instillation (4 grams) once a day, preferably at bedtime, and retained for approximately eight hours for 3 to 6 weeks depending on symptoms and sigmoidoscopic findings. (2)
- Drink an adequate amount of fluids. (2. 5.7)
Dosing: Altered kidney function
8.6 Renal Impairment Mesalamine is known to be substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function. Evaluate renal function in all patients prior to initiation and periodically while on ROWASA therapy. Monitor patients with known renal impairment or history of renal disease or taking nephrotoxic drugs for decreased renal function and mesalamine-related adverse reactions. Discontinue ROWASA if renal function deteriorates while on therapy [see Warnings and Precautions (5.2)].
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Clinical trials of ROWASA did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. Reports from uncontrolled clinical studies and postmarketing reporting systems suggested a higher incidence of blood dyscrasias (i.e., agranulocytosis, neutropenia and pancytopenia) in patients receiving mesalamine-containing products such as ROWASA who were 65 years or older compared to younger adult patients, which may also be associated with ulcerative colitis, use of interacting drugs, or reduced renal function.
Consider monitoring complete blood cell counts and platelet counts in patients 65 years and over during treatment with ROWASA. In general, consider the greater frequency of decreased hepatic, renal, or cardiac function, and of concurrent disease or other drug therapy in patients 65 years and over when prescribing ROWASA.
Dosage forms
Philippines
- Gastro-resistant prolonged-release granule: 1 g per sachet, 1.5 g per Sachet, 3 g per sachet, 500 mg per sachet
- Rectal suppository: 1 g, 250 mg, 500 mg
- Suppository: 1 g, 250 mg, 500 mg
- Prolonged-release tablet: 1 g, 500 mg
- Enteric-coated tablet: 500 mg
- Prolonged-release granule: 2 g
- Rectal suspension for enema: 4 g/60 mL
Registered products in the Philippines
17 products registered with the Food and Drug Administration (FDA) Philippines list Mesalazine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products17
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
MecolzineMesalazine | 500 mg Rectal SuppositoryPVC/PE film shell x 5's (Box of 100's) | Rx | Laboratorios Vitoria, S.A.Portugal | Buergli Pharma, Inc.Trader: FAES FARMA, S.A. | DR-XY48315 | Aug 26, 2027 | |
Mesadian 1000Mesalazine | 1g Rectal SuppositoryOpaque White PVC/PE Peelable Film Blister x 5's (Box of 10's) | Rx | Meridian Enterprises Pvt. Ltd.India | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-15859 | Sep 24, 2029 | |
Mesadian 250Mesalazine | 250 mg SuppositoryAlu/PVC/PE Blister pack x 5's (Box of 10's) | Rx | Meridian Enterprises Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-16966 | Sep 2, 2030 | |
Mesadian-500Mesalazine | 500 mg Rectal SuppositoryWhite PVC/PE strip pack x 5's (Box of 60's) | Rx | Meridian Enterprises Pvt. Ltd.India | AMB HK Enterprises Inc. | DR-XY49532 | Oct 1, 2030 | |
MisalMesalazine | 1 g SuppositoryPVC/PE strip of 5's (Box of 10's) | Rx | Kusum Healthcare Pvt. Ltd.India | Kusum Healthcare Private Limited Branch Office | DR-XY48271 | Aug 10, 2027 | |
MisalMesalazine | 500 mg SuppositoryPVC/PE Strips of 5's (Box of 10's) | Rx | Kusum Healthcare Pvt. Ltd. (Block II)India | Kusum Healthcare Private Limited Branch Office | DR-XY49259 | Oct 29, 2029 | |
PentasaMesalazine | 1 g Prolonged-Release TabletAlu/Alu Blister Pack x 10's (Box of 60's) | Rx | Ferring International Center SASwitzerland | Metro Drug, Inc. | DR-XY43892 | Nov 14, 2029 | |
PentasaMesalazine | 1g SuppositoryAlu/Alu Blister Pack x 7's (Box of 28's) | Rx | Ferring International Center SASwitzerland | Metro Drug, Inc. | DR-XY38376 | Jun 21, 2027 | |
PentasaMesalazine | 2 g Prolonged Release GranulesPolyester/Alu/LDPE Foil Sachet x 2.12 g (Box of 60 sachets) | Rx | Ferring International Center SASwitzerland | Metro Drug, Inc. | DR-XY48195 | Jul 15, 2027 | |
PentasaMesalazine | 500 mg Prolonged-Release TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Ferring International Center SASwitzerland | Importer: Metro Drug, Inc. | DR-XY26649 | Mar 6, 2028 | |
SalofalkMesalazine | 1 g per sachet Gastro-Resistant Prolonged Release GranulesPETP/Alu/LDPE Foil Sachet x 1.860 g Box of 50’s | Rx | Losan Pharma GmbHGermany | Importer: A. Menarini Philippines, Inc.Trader: Dr. Falk Pharma GmbH | DR-XY43336 | May 15, 2029 | |
SalofalkMesalazine | 1.5 g per Sachet Gastro-Resistant Prolonged Release GranulesPETP/Alu/LDPE Foil Sachet x 2.79 g Box of 35’s and 60's Sachets) | Rx | Losan Pharma GmbHGermany | Importer: A. Menarini Philippines, Inc. | DR-XY43335 | May 15, 2029 | |
SalofalkMesalazine | 250 mg Rectal SuppositoryPVC/PE Blister Pack x 5’s Box of 30’s | Rx | Corden Pharma Fribourg SASwitzerland | Importer: A. Menarini Philippines, Inc.Trader: Dr. Falk Pharma GmbH | DR-XY19513 | Oct 15, 2029 | |
SalofalkMesalazine | 3 g per sachet Gastro-Resistant Prolonged Release GranulesPETP/Alu/LDPE Foil Sachet x 5.58 g (Box of 20’s) | Rx | Losan Pharma GmbHGermany | Importer: A. Menarini Philippines, Inc.Trader: Dr. Falk Pharma GmbH | DR-XY43334 | Apr 15, 2029 | |
SalofalkMesalazine | 4 g/60 mL Rectal Suspension for EnemaIn white flexible synthetic concertina below with extersion tube packed in secondary gas tight blister type packaging x 60 mL (Box of 7's) | Rx | Corden Pharma Fribourg SASwitzerland | Importer: A. Menarini Philippines, Inc.Trader: Dr. Falk Pharma GmbH | DR-XY21227 | Apr 26, 2030 | |
SalofalkMesalazine | 500 mg Enteric-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 100's) | Rx | Losan Pharma GmbHGermany | A. Menarini Philippines, Inc.Trader: Dr. Falk Pharma GmbH | DR-XY21352 | Feb 24, 2030 | |
SalofalkMesalazine | 500 mg per sachet Gastro-Resistant Prolonged Release GranulesPETP/Alu/LDPE Foil Sachet x 930 mg (Box of 50’s) | Rx | Losan Pharma GmbHGermany | Importer: A. Menarini Philippines, Inc.Trader: Dr. Falk Pharma GmbH | DR-XY43333 | May 15, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Rectal Suspension: 4 g/60 mL enema bottle; off-white to tan colored suspension Rectal Suspension: 4 g/60 mL enema bottle (3)
Warnings/Precautions
- • Hypersensitivity Reactions: Sulfite-related reactions (ROWASA contains potassium metabisulfite) and sulfasalazine-associated reactions (myocarditis and pericarditis) can occur; evaluate patients immediately and discontinue ROWASA if a hypersensitivity reaction is suspected. (5.3)
- • Renal Impairment: Assess renal function at the beginning of treatment and periodically during treatment. Evaluate the risks and benefits of ROWASA in patients with known renal impairment or taking nephrotoxic drug. Discontinue ROWASA if renal function deteriorates while on therapy. (5.1, 7.1)
- • Mesalamine-Induced Acute Intolerance Syndrome: Discontinue treatment if acute intolerance syndrome (cramping, acute abdominal pain, bloody diarrhea, sometimes fever, headache and rash) is suspected. (5.2)
- • Hepatic Failure: Evaluate the risks and benefits of using ROWASA in patients with known liver impairment. (5.4)
- • Severe Cutaneous Adverse Reactions: Discontinue at the first signs or symptoms of severe cutaneous adverse reactions or other signs of hypersensitivity and consider further evaluation. (5.5)
- • Photosensitivity: Avoid sun exposure if pre-existing skin conditions. (5.6)
- • Nephrolithiasis: Cases of nephrolithiasis have been reported with the use of mesalamine. Mesalamine-containing stones are undetectable by standard radiography or computed tomography (CT). Ensure adequate …
5.1 Hypersensitivity Reactions Sulfite-Related
5.1 Hypersensitivity Reactions Sulfite-Related Reactions ROWASA contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but probably low.
Sulfite sensitivity is seen more frequently in asthmatic or in atopic nonasthmatic persons. Epinephrine is the preferred treatment for serious allergic or emergency situations even though epinephrine injection contains sodium or potassium metabisulfite with the above-mentioned potential liabilities. The alternatives to using epinephrine in a life-threatening situation may not be satisfactory.
The presence of a sulfite(s) in epinephrine injection should not deter the administration of the drug for treatment of serious allergic or other emergency situations. Sulfasalazine-Associated Reactions Hypersensitivity reactions have been reported in patients taking sulfasalazine. Some patients may have a similar reaction to ROWASA or to other compounds that contain or are converted to mesalamine.
As with sulfasalazine, mesalamine-induced hypersensitivity reactions may present as internal organ involvement, including myocarditis, pericarditis, nephritis, hepatitis, pneumonitis and hematologic abnormalities. Evaluate patients immediately if signs or symptoms of a hypersensitivity reaction are present. Discontinue ROWASA if an alternative etiology for the signs and symptoms cannot be established.
5.2 Renal Impairment
5.2 Renal Impairment Renal impairment, including minimal change disease, acute and chronic interstitial nephritis, and renal failure have been reported in patients given ROWASA or other products that contain mesalamine or are converted to mesalamine. In animal studies, the kidney was the principal organ of mesalamine toxicity [see Nonclinical Toxicology (13.2)].
Evaluate the risks and benefits of using ROWASA in patients with known renal impairment or a history of renal disease or taking concomitant nephrotoxic drugs. Evaluate renal function in all patients prior to initiation and periodically while on ROWASA therapy. Discontinue ROWASA if renal function deteriorates while on therapy [see Drug Interactions (7.1), Use in Specific Populations (8.6)].
5.3 Mesalamine-Induced Acute Intolerance Syndrome
5.3 Mesalamine-Induced Acute Intolerance Syndrome Mesalamine has been associated with an acute intolerance syndrome that may be difficult to distinguish from a flare of inflammatory bowel disease. Although the exact frequency of occurrence cannot be ascertained, it has occurred in 3% of patients in controlled clinical trials of mesalamine or sulfasalazine.
Symptoms include cramping, acute abdominal pain and bloody diarrhea, sometimes fever, headache, and rash. Monitor patients for worsening of these symptoms while on treatment. If acute intolerance syndrome is suspected, promptly discontinue treatment with ROWASA.
5.4 Hepatic Failure
5.4 Hepatic Failure There have been reports of hepatic failure in patients with pre-existing liver disease who have been administered other products containing mesalamine. Evaluate the risks and benefits of using ROWASA in patients with known liver impairment.
5.5 Severe Cutaneous Adverse Reactions
5.5 Severe Cutaneous Adverse Reactions Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP) have been reported with the use of mesalamine [see Adverse Reactions (6)]. Discontinue ROWASA at the first signs or symptoms of severe cutaneous adverse reactions or other signs of hypersensitivity and consider further evaluation.
5.6 Photosensitivity
5.6 Photosensitivity Patients with pre‑existing skin conditions such as atopic dermatitis and atopic eczema have reported more severe photosensitivity reactions. Advise patients to avoid sun exposure, wear protective clothing, and use a broad-spectrum sunscreen when outdoors.
5.7 Nephrolithiasis
5.7 Nephrolithiasis Cases of nephrolithiasis have been reported with the use of mesalamine, including stones with 100% mesalamine content. Mesalamine‑containing stones are radiotransparent and undetectable by standard radiography or computed tomography (CT). Ensure adequate fluid intake during treatment.
5.8 Interference with Laboratory Tests
5.8 Interference with Laboratory Tests Use of mesalamine may lead to spuriously elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection because of the similarity in the chromatograms of normetanephrine and the main metabolite of mesalamine, N‑acetyl‑5‑aminosalicylic acid (N‑Ac‑5‑ASA). Consider an alternative, selective assay for normetanephrine.
5.9 Intracranial Hypertension
5.9 Intracranial Hypertension Intracranial hypertension has been reported postmarketing in patients receiving mesalamine and sulfasalazine. Signs and symptoms of intracranial hypertension can include severe or recurrent headache, blurred vision, diplopia, and potential vision loss; papilledema can be found on fundoscopy.
These signs and symptoms are similar to idiopathic intracranial hypertension. If an unusual headache or visual disturbance occurs during treatment, immediately discontinue ROWASA and refer the patient for further evaluation.
Drug interactions
- • Nephrotoxic Agents including Non-Steroidal Anti-inflammatory Drugs (NSAIDs): Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (7.1)
- • Azathioprine or 6-Mercaptopurine: Increased risk of blood dyscrasias; monitor complete blood cell counts and platelet counts. (7.2)
7.1 Nephrotoxic Agents, Including Non-Steroidal Anti-Inflammatory Drugs
7.1 Nephrotoxic Agents, Including Non-Steroidal Anti-Inflammatory Drugs The concurrent use of mesalamine with known nephrotoxic agents, including non‑steroidal anti‑inflammatory drugs (NSAIDs), may increase the risk of nephrotoxicity. Monitor patients taking nephrotoxic drugs for changes in renal function and mesalamine-related adverse reactions [see Warnings and Precautions (5.2)].
7.2 Azathioprine or 6
7.2 Azathioprine or 6-Mercaptopurine The concurrent use of mesalamine with azathioprine or 6‑mercaptopurine and/or any other drugs known to cause myelotoxicity may increase the risk for blood disorders, bone marrow failure, and associated complications. If concomitant use of ROWASA and azathioprine or 6-mercaptopurine cannot be avoided, monitor blood tests, including complete blood cell counts and platelet counts.
7.3 Interference with Urinary Normetanephrine Measurements Use
7.3 Interference with Urinary Normetanephrine Measurements Use of ROWASA may lead to spuriously elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection [see Warnings and Precautions (5.8)]. Consider an alternative, selective assay for normetanephrine.
Adverse reactions
- The following clinically significant adverse reactions are described elsewhere in the labeling: • Hypersensitivity reactions [see Warnings and Precautions (5.1)] • Renal impairment [see Warnings and Precautions (5.2)] • Mesalamine-induced acute intolerance syndrome [see Warnings and Precautions (5.3)] • Hepatic failure [see Warnings and Precautions (5.4)] • Severe cutaneous adverse reactions [see Warnings and Precautions (5.5)] • Photosensitivity [see Warnings and Precautions (5.6)] • Nephrolithiasis [see Warnings and Precautions (5.7)] • Intracranial Hypertension [see Warnings and Precautions (5.9)] Most common adverse reactions (≥1%) are: gas/flatulence, flu, fever, leg/joint pain, hemorrhoids, rectal pain and hair loss. (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc at 1-866-210-5949 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Table 1: Adverse Reactions reported in 1% or more of ROWASA-treated patients and greater than placebo in Clinical Trials of ROWASA in Adult Patients with Ulcerative Colitis, Proctosigmoiditis or Proctitis Adverse Reaction ROWASA (N=815) % Placebo (N=128) % Gas/Flatulence 6 4 Flu 5 1 Fever 3 0 Leg/Joint pain 2 1 Hemorrhoids 1 1 Rectal pain 1 0 Hair loss 1 0
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during post‑approval use of mesalamine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Cardiac Disorders: myocarditis, pericarditis [see Warnings and Precautions (5.1)] Gastrointestinal Disorders: pancreatitis Hematologic Disorders: agranulocytosis, aplastic anemia, eosinophilia, leukopenia, neutropenia, pancytopenia, thrombocytopenia Hepatic Disorders: elevated liver enzymes, hepatic failure [see Warnings and Precautions (5.4)] Immune System Disorders: vasculitis Nervous System: intracranial hypertension Renal and Urinary Disorders: acute renal failure, chronic renal failure, interstitial nephritis, nephrogenic diabetes insipidus, nephrolithiasis, nephrotoxicity [see Warnings and Precautions (5.2), (5.7)]
- Urine discoloration occurring ex-vivo caused by contact of mesalamine including inactive metabolite, with surfaces or water treated with hypochlorite-containing bleach Reproductive System and Breast Disorders: reversible oligospermia Respiratory, Thoracic, and Mediastinal Disorders: fibrosing alveolitis, pleurisy/pleuritis Skin and Subcutaneous Tissue Disorders: AGEP, DRESS, SJS/TEN [see Warnings and Precautions (5.5)]
Adverse reaction frequency tables (US label) US FDA label
| Adverse Reaction | ROWASA (N=815) % | Placebo (N=128) % |
| Gas/Flatulence | 6 | 4 |
| Flu | 5 | 1 |
| Fever | 3 | 0 |
| Leg/Joint pain | 2 | 1 |
| Hemorrhoids | 1 | 1 |
| Rectal pain | 1 | 0 |
| Hair loss | 1 | 0 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Published data from meta-analyses, cohort studies and case series on the use of mesalamine during pregnancy have not reliably informed an association with mesalamine and major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data). There are adverse effects on maternal and fetal outcomes associated with ulcerative colitis in pregnancy (see Clinical Considerations).
In animal reproduction studies, rats and rabbits administered mesalamine during organogenesis at oral doses up to 5 and 8 times the maximum recommended human dose, respectively, did not reveal any evidence of harm to the embryo or the fetus (see Data). The background risk of major birth defects and miscarriage for the indicated population is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated maternal and embryo/fetal risk Published data suggest that increased disease activity is associated with the risk of developing adverse pregnancy outcomes in women with ulcerative colitis.
Adverse pregnancy outcomes include preterm delivery (before 37 weeks of gestation), low birth weight (less than 2500 g) infants, and small for gestational age at birth. Data Human Data Published data from meta-analyses, cohort studies and case series on the use of mesalamine, the active moiety of ROWASA, during early pregnancy (first trimester) and throughout pregnancy have not reliably informed an association of mesalamine and major birth defects, miscarriage, or adverse maternal or fetal outcomes.
There is no clear evidence that mesalamine exposure in early pregnancy is associated with an increased risk in major congenital malformations, including cardiac malformations. Published epidemiologic studies have important methodological limitations which hinder interpretation of the data, including inability to control for confounders, such as underlying maternal disease, and maternal use of concomitant medications, and missing information on the dose and duration of use for mesalamine products.
Animal Data Reproduction studies have been performed with mesalamine in rats and rabbits during organogenesis at oral doses up to 5 and 8 times respectively, the maximum recommended human dose, and have revealed no evidence of harm to the embryo or the fetus.
Mechanism of action
12.1 Mechanism of Action The mechanism of action of 5-ASA (mesalamine) is not fully understood, but appears to be a topical anti-inflammatory effect on colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways (i.e., prostanoids), and through the lipoxygenase pathways (i.e., leukotrienes and hydroxyeicosatetraenoic acids) is increased in patients with ulcerative colitis, and it is possible that mesalamine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of mesalamine have not been fully characterized.
Pharmacokinetics
12.3 Pharmacokinetics Absorption Mesalamine administered rectally as ROWASA is poorly absorbed from the colon and is excreted principally in the feces during subsequent bowel movements.
Excretion Whatever the metabolic site, most of the absorbed mesalamine is excreted in the urine as the N-acetyl-5-ASA metabolite.
While the elimination half-life of mesalamine is short (0.5 to 1.5 hours), the acetylated metabolite exhibits a half-life of 5 to 10 hours.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption Mesalamine administered rectally as ROWASA is poorly absorbed from the colon and is excreted principally in the feces during subsequent bowel movements. The extent of absorption is dependent upon the retention time of the drug product, and there is considerable individual variation. Under clinical conditions patients demonstrated plasma levels 10 to 12 hours post mesalamine administration of 2 mcg/mL, about two-thirds of which was the N-acetyl metabolite.
In addition, steady state plasma levels demonstrated a lack of accumulation of either parent drug or N-acetyl metabolite during repeated daily rectal administrations. Distribution Other than the kidney, the organ distribution and other bioavailability characteristics of absorbed mesalamine in man are not known. The poor colonic absorption of rectally administered mesalamine is substantiated by the low serum concentration of 5-ASA and N-acetyl-5-ASA seen in ulcerative colitis patients after dosage with mesalamine.
Elimination Metabolism It is known that the compound undergoes acetylation but whether this process takes place at colonic or systemic sites has not been elucidated. Excretion Whatever the metabolic site, most of the absorbed mesalamine is excreted in the urine as the N-acetyl-5-ASA metabolite. At steady state, approximately 10 to 30% of the daily 4-gram dose can be recovered in cumulative 24-hour urine collections.
While the elimination half-life of mesalamine is short (0.5 to 1.5 hours), the acetylated metabolite exhibits a half-life of 5 to 10 hours.
Formulary and pricing (Philippines)
Formulary and coverage
| Philippine National Formulary | Listed as Mesalazine |
| PNF listing | Oral: 500 mg enteric coated tabletRestrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1) |
| PNF listing | Oral: 500 mg enteric MR tabletRestrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1) |
| PNF listing | Rectal: 250 mg suppositoryRestrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1) |
| PNF listing | Sachet: 1.5 g gastro-resistant prolonged release (PR) granulesRestrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Rowasa · Viatris Specialty LLC [US FDA-approved label, version 18, August 3, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e505ab99-1943-4216-a178-4d5dbe64e3b2
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .